Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY6 | Q15077 | 2/20 | 0.32 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.31 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1060591 | 0.90 | POLB (0.38) | P2RY6PTPN2PTPN1CYP3A4 | |
| SCHEMBL1060276 | 0.85 | PRMT6 (0.42) | — | |
| SCHEMBL1058381 | 0.84 | TK1 (0.37) | — | |
| SCHEMBL1054675 | 0.80 | TDP1 (0.34) | — | |
| SCHEMBL26123372 | 0.77 | P2RY6 (0.37) | P2RY6PTPN2PTPN1 | |
| SCHEMBL26124617 | 0.77 | P2RY6 (0.37) | P2RY6PTPN2PTPN1 | |
| SCHEMBL1061496 | 0.77 | KDM4E (0.38) | — | |
| SCHEMBL5879007 | 0.76 | ELANE (0.34) | — | |
| SCHEMBL26122705 | 0.74 | P2RY6 (0.42) | P2RY6PTPN2PTPN1 | |
| SCHEMBL26122701 | 0.74 | P2RY6 (0.42) | P2RY6PTPN2PTPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1152009-B2 | NOVEL NUCLEOSIDES AND OLIGONUCLEOTIDE ANALOGUES | DAIICHI SANKYO CO LTD (JP) | 2017-09-06 | — | — | EP | disclosed |
| US-8957201-B2 | Oligonucleotide analogues and methods utilizing the same | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2015-02-17 | — | — | US | disclosed |
| US-20110009471-A1 | Oligonucleotide analogues and methods utilizing the same | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2011-01-13 | — | — | US | disclosed |
| US-7314923-B2 | Nucleoside and oligonucleotide analogues | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2008-01-01 | — | — | US | disclosed |
| EP-1152009-B1 | NOVEL NUCLEOSIDES AND OLIGONUCLEOTIDE ANALOGUES | SANKYO CO (JP) | 2005-01-26 | — | — | EP | disclosed |
| US-20030207841-A1 | Novel nucleoside and oligonucleotide analogues | SANKYO COMPANY LIMITED (JP) | 2003-11-06 | — | — | US | disclosed |
| EP-1152009-A1 | NOVEL NUCLEOSIDES AND OLIGONUCLEOTIDE ANALOGUES | Sankyo Company, Limited (JP) | 2001-11-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110009471-A1 | Oligonucleotide analogues and methods utilizing the same | NSUN2, RNGTT, DUT | P2RY6 1164/4885PTPN2 2106/4885PTPN1 2472/4885 |
| US-20030207841-A1 | Novel nucleoside and oligonucleotide analogues | RNGTT, NSUN2, MTAP | P2RY6 237/4885PTPN2 2741/4885PTPN1 1780/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.